You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output.
Click here to find out more.
X Demographics
Mendeley readers
Attention Score in Context
| Title |
Palbociclib: a first-in-class CDK4/CDK6 inhibitor for the treatment of hormone-receptor positive advanced breast cancer
|
|---|---|
| Published in |
Journal of Hematology & Oncology, August 2015
|
| DOI | 10.1186/s13045-015-0194-5 |
| Pubmed ID | |
| Authors |
Janice Lu |
| Abstract |
Palbociclib was approved by the FDA for use in combination with letrozole for the treatment of postmenopausal women with hormone-receptor-positive, HER2-negative advanced breast cancer as initial endocrine-based therapy. In addition, the combination of palbociclib with fulvestrant resulted in superior outcome than fulvestrant alone in those who had progressed during prior endocrine therapy. This research highlight summarized the current development of CDK4/CDK6 inhibitors and future directions in the treatment of advanced hormone-receptor-positive breast cancer. |
X Demographics
The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 1 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 1 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 80 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Netherlands | 1 | 1% |
| United Kingdom | 1 | 1% |
| Egypt | 1 | 1% |
| Japan | 1 | 1% |
| United States | 1 | 1% |
| Unknown | 75 | 94% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Ph. D. Student | 10 | 13% |
| Researcher | 10 | 13% |
| Student > Bachelor | 9 | 11% |
| Other | 7 | 9% |
| Student > Master | 5 | 6% |
| Other | 14 | 18% |
| Unknown | 25 | 31% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 22 | 28% |
| Biochemistry, Genetics and Molecular Biology | 12 | 15% |
| Pharmacology, Toxicology and Pharmaceutical Science | 6 | 8% |
| Agricultural and Biological Sciences | 5 | 6% |
| Chemistry | 4 | 5% |
| Other | 7 | 9% |
| Unknown | 24 | 30% |
Attention Score in Context
This research output has an Altmetric Attention Score of 11. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 30 June 2022.
All research outputs
#2,861,684
of 22,769,322 outputs
Outputs from Journal of Hematology & Oncology
#202
of 1,189 outputs
Outputs of similar age
#38,715
of 264,323 outputs
Outputs of similar age from Journal of Hematology & Oncology
#2
of 14 outputs
Altmetric has tracked 22,769,322 research outputs across all sources so far. Compared to these this one has done well and is in the 87th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 1,189 research outputs from this source. They typically receive more attention than average, with a mean Attention Score of 9.6. This one has done well, scoring higher than 83% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 264,323 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 85% of its contemporaries.
We're also able to compare this research output to 14 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 85% of its contemporaries.